


AMENDMENTS TO THE CLAIMS

1. - 4. (Cancelled)

5. (Previously Presented) An aryl ureido compound, represented by Formula IIa,



wherein,

R' represents hydrogen or alkyl; and

R¹ represents hydrogen or alkyl; and

R² represents halo; and

R³ and R⁴, independently of each other, represent hydrogen, halo, hydroxy, alkoxy, haloalkyl; or

R³ and R⁴ together form a methylenedioxy ring of the structure -O-CH₂-O-; or

R³ and R⁴ together form a benzo-fused ring, which fused ring is optionally substituted one or more times with substituents selected from halo, hydroxy, alkoxy and haloalkyl.

6. (Original) The aryl ureido derivative of claim 5, which is

2-[3-(3-Bromo-phenyl)-ureido]-4-chloro-5-methyl-benzenesulfonic acid;

4-Chloro-5-methyl-2-[3-(3-trifluoromethyl-phenyl)-ureido]-benzenesulphonic acid;

4-Chloro-2-[3-(3-trifluoromethyl-phenyl)-ureido]-benzenesulphonic acid;

2-[3-(3-Bromo-phenyl)-ureido]-4-chloro-benzenesulfonic acid; or

4-Chloro-5-methyl-2-(3-naphthalen-2-yl-ureido)-benzenesulphonic acid;

or an enantiomer or a mixture of enantiomers, or a pharmaceutically-acceptable addition salt thereof.

7. - 26. (Cancelled)

27. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a chemical compound of claim 5, or a pharmaceutically-acceptable addition salt thereof, and a pharmaceutically acceptable carrier.

28. - 33. (Cancelled)